A multicentre study on high-frequency ultrasound evaluation of the skin and joints in patients with psoriatic arthritis treated with infliximab
Our objective was to describe the ultrasound features of patients with PsA in joints and skin and their changes after treatment with infliximab. Eight hospitals recruited PsA active patients. Clinical (joint count for pain, TJC, and swelling, SJC, pain VAS, ESR, C-reactive protein and PASI) and US v...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental rheumatology 2012-11, Vol.30 (6), p.879-885 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 885 |
|---|---|
| container_issue | 6 |
| container_start_page | 879 |
| container_title | Clinical and experimental rheumatology |
| container_volume | 30 |
| creator | DE AGUSTIN, J. J MORAGUES, C DE MIGUEL, E MÖLLER, I ACEBES, C NAREDO, E USON, J REJON, E MAYORDOMO, L GARRIDO, J |
| description | Our objective was to describe the ultrasound features of patients with PsA in joints and skin and their changes after treatment with infliximab.
Eight hospitals recruited PsA active patients. Clinical (joint count for pain, TJC, and swelling, SJC, pain VAS, ESR, C-reactive protein and PASI) and US variables (plaque thickness, PD signal of dermal lesions, synovitis, erosions, and PD signal, assessed by 4-category ordinal scales) were independently recorded at baseline and 4, 12 and 24-week after starting treatment with infliximab. The results were analysed with paired T, Wilcoxon test, ANOVA and marginal homogeneity test.
Changes in 24 patients from baseline to last available data were significant for clinical variables, pain VAS, TJC and SJC as well as for ESR, CRP (all p |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1273219703</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1273219703</sourcerecordid><originalsourceid>FETCH-LOGICAL-p241t-cc7155a42a7e6b8e3a21107c9c9635727e9098a1e3afb187cb74f1a9b54959473</originalsourceid><addsrcrecordid>eNpF0MlOwzAQAFALgWhZfgH5gsQlkpc4jo9VxSZV4gJSb9HEcYhL6gTbAfoV_DJGLeLkZZ7HM3OE5lQonhFVro_RnHDFslIU6xk6C2FDCCtEIU_RjHHCSFkUc_S9wNupj1YbF73BIU7NDg8Od_a1y1pv3ifj9A4n4iEMk2uw-YB-gmgTGlocu_TozToMKbQZrIsBp9OYgPndf9rY4TEM3qYbjcHHzttoA06_QTTNHljX9vbLbqG-QCct9MFcHtZz9HJ3-7x8yFZP94_LxSobWU5jprWkQkDOQJqiLg0HRimRWmlVcCGZNCrNAGgKtDUtpa5l3lJQtciVULnk5-hmn3f0Q-oxxGprgzZ9D84MU6gok5xRJQlP9OpAp3prmmr0qVC_q_6GmMD1AUDQ0LcenLbh3xWlSLkI_wEQdn8M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1273219703</pqid></control><display><type>article</type><title>A multicentre study on high-frequency ultrasound evaluation of the skin and joints in patients with psoriatic arthritis treated with infliximab</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>DE AGUSTIN, J. J ; MORAGUES, C ; DE MIGUEL, E ; MÖLLER, I ; ACEBES, C ; NAREDO, E ; USON, J ; REJON, E ; MAYORDOMO, L ; GARRIDO, J</creator><creatorcontrib>DE AGUSTIN, J. J ; MORAGUES, C ; DE MIGUEL, E ; MÖLLER, I ; ACEBES, C ; NAREDO, E ; USON, J ; REJON, E ; MAYORDOMO, L ; GARRIDO, J</creatorcontrib><description>Our objective was to describe the ultrasound features of patients with PsA in joints and skin and their changes after treatment with infliximab.
Eight hospitals recruited PsA active patients. Clinical (joint count for pain, TJC, and swelling, SJC, pain VAS, ESR, C-reactive protein and PASI) and US variables (plaque thickness, PD signal of dermal lesions, synovitis, erosions, and PD signal, assessed by 4-category ordinal scales) were independently recorded at baseline and 4, 12 and 24-week after starting treatment with infliximab. The results were analysed with paired T, Wilcoxon test, ANOVA and marginal homogeneity test.
Changes in 24 patients from baseline to last available data were significant for clinical variables, pain VAS, TJC and SJC as well as for ESR, CRP (all p<0.0005). Dermatological PASI changed from 14.6±14.9 to 2.1±4.1 and plaque thickness from 3.34±1.75 mm to 1.74±0.96 mm (both p<0.0005); synovitis and PD signal improved (both p<0.0005). Psoriatic plaque PD improved across the study (p<0.0005) with no signal increasing from 36.4% to 88.9% and positive PD signal decreasing from 63.6% to 11.1% of the plaques.
Treatment with anti-TNF-α infliximab improves the symptoms of patients with PsA at joint and psoriatic skin levels from a clinical and ultrasonographic perspective.</description><identifier>ISSN: 0392-856X</identifier><identifier>EISSN: 1593-098X</identifier><identifier>PMID: 23020866</identifier><language>eng</language><publisher>Pisa: Clinical and Experimental Rheumatology</publisher><subject>Adult ; Anti-Inflammatory Agents - therapeutic use ; Antibodies, Monoclonal - therapeutic use ; Arthritis, Psoriatic - diagnostic imaging ; Arthritis, Psoriatic - drug therapy ; Arthritis, Psoriatic - pathology ; Biological and medical sciences ; Dermatology ; Diseases of the osteoarticular system ; Diseases of the spine ; Female ; Humans ; Inflammatory joint diseases ; Infliximab ; Joints - diagnostic imaging ; Joints - drug effects ; Joints - pathology ; Male ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Observer Variation ; Predictive Value of Tests ; Prospective Studies ; Psoriasis. Parapsoriasis. Lichen ; Reproducibility of Results ; Severity of Illness Index ; Skin - diagnostic imaging ; Skin - drug effects ; Skin - pathology ; Spain ; Time Factors ; Treatment Outcome ; Ultrasonography, Doppler ; Young Adult</subject><ispartof>Clinical and experimental rheumatology, 2012-11, Vol.30 (6), p.879-885</ispartof><rights>2014 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26853210$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23020866$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DE AGUSTIN, J. J</creatorcontrib><creatorcontrib>MORAGUES, C</creatorcontrib><creatorcontrib>DE MIGUEL, E</creatorcontrib><creatorcontrib>MÖLLER, I</creatorcontrib><creatorcontrib>ACEBES, C</creatorcontrib><creatorcontrib>NAREDO, E</creatorcontrib><creatorcontrib>USON, J</creatorcontrib><creatorcontrib>REJON, E</creatorcontrib><creatorcontrib>MAYORDOMO, L</creatorcontrib><creatorcontrib>GARRIDO, J</creatorcontrib><title>A multicentre study on high-frequency ultrasound evaluation of the skin and joints in patients with psoriatic arthritis treated with infliximab</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>Our objective was to describe the ultrasound features of patients with PsA in joints and skin and their changes after treatment with infliximab.
Eight hospitals recruited PsA active patients. Clinical (joint count for pain, TJC, and swelling, SJC, pain VAS, ESR, C-reactive protein and PASI) and US variables (plaque thickness, PD signal of dermal lesions, synovitis, erosions, and PD signal, assessed by 4-category ordinal scales) were independently recorded at baseline and 4, 12 and 24-week after starting treatment with infliximab. The results were analysed with paired T, Wilcoxon test, ANOVA and marginal homogeneity test.
Changes in 24 patients from baseline to last available data were significant for clinical variables, pain VAS, TJC and SJC as well as for ESR, CRP (all p<0.0005). Dermatological PASI changed from 14.6±14.9 to 2.1±4.1 and plaque thickness from 3.34±1.75 mm to 1.74±0.96 mm (both p<0.0005); synovitis and PD signal improved (both p<0.0005). Psoriatic plaque PD improved across the study (p<0.0005) with no signal increasing from 36.4% to 88.9% and positive PD signal decreasing from 63.6% to 11.1% of the plaques.
Treatment with anti-TNF-α infliximab improves the symptoms of patients with PsA at joint and psoriatic skin levels from a clinical and ultrasonographic perspective.</description><subject>Adult</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Arthritis, Psoriatic - diagnostic imaging</subject><subject>Arthritis, Psoriatic - drug therapy</subject><subject>Arthritis, Psoriatic - pathology</subject><subject>Biological and medical sciences</subject><subject>Dermatology</subject><subject>Diseases of the osteoarticular system</subject><subject>Diseases of the spine</subject><subject>Female</subject><subject>Humans</subject><subject>Inflammatory joint diseases</subject><subject>Infliximab</subject><subject>Joints - diagnostic imaging</subject><subject>Joints - drug effects</subject><subject>Joints - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Observer Variation</subject><subject>Predictive Value of Tests</subject><subject>Prospective Studies</subject><subject>Psoriasis. Parapsoriasis. Lichen</subject><subject>Reproducibility of Results</subject><subject>Severity of Illness Index</subject><subject>Skin - diagnostic imaging</subject><subject>Skin - drug effects</subject><subject>Skin - pathology</subject><subject>Spain</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Ultrasonography, Doppler</subject><subject>Young Adult</subject><issn>0392-856X</issn><issn>1593-098X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0MlOwzAQAFALgWhZfgH5gsQlkpc4jo9VxSZV4gJSb9HEcYhL6gTbAfoV_DJGLeLkZZ7HM3OE5lQonhFVro_RnHDFslIU6xk6C2FDCCtEIU_RjHHCSFkUc_S9wNupj1YbF73BIU7NDg8Od_a1y1pv3ifj9A4n4iEMk2uw-YB-gmgTGlocu_TozToMKbQZrIsBp9OYgPndf9rY4TEM3qYbjcHHzttoA06_QTTNHljX9vbLbqG-QCct9MFcHtZz9HJ3-7x8yFZP94_LxSobWU5jprWkQkDOQJqiLg0HRimRWmlVcCGZNCrNAGgKtDUtpa5l3lJQtciVULnk5-hmn3f0Q-oxxGprgzZ9D84MU6gok5xRJQlP9OpAp3prmmr0qVC_q_6GmMD1AUDQ0LcenLbh3xWlSLkI_wEQdn8M</recordid><startdate>20121101</startdate><enddate>20121101</enddate><creator>DE AGUSTIN, J. J</creator><creator>MORAGUES, C</creator><creator>DE MIGUEL, E</creator><creator>MÖLLER, I</creator><creator>ACEBES, C</creator><creator>NAREDO, E</creator><creator>USON, J</creator><creator>REJON, E</creator><creator>MAYORDOMO, L</creator><creator>GARRIDO, J</creator><general>Clinical and Experimental Rheumatology</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20121101</creationdate><title>A multicentre study on high-frequency ultrasound evaluation of the skin and joints in patients with psoriatic arthritis treated with infliximab</title><author>DE AGUSTIN, J. J ; MORAGUES, C ; DE MIGUEL, E ; MÖLLER, I ; ACEBES, C ; NAREDO, E ; USON, J ; REJON, E ; MAYORDOMO, L ; GARRIDO, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p241t-cc7155a42a7e6b8e3a21107c9c9635727e9098a1e3afb187cb74f1a9b54959473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Arthritis, Psoriatic - diagnostic imaging</topic><topic>Arthritis, Psoriatic - drug therapy</topic><topic>Arthritis, Psoriatic - pathology</topic><topic>Biological and medical sciences</topic><topic>Dermatology</topic><topic>Diseases of the osteoarticular system</topic><topic>Diseases of the spine</topic><topic>Female</topic><topic>Humans</topic><topic>Inflammatory joint diseases</topic><topic>Infliximab</topic><topic>Joints - diagnostic imaging</topic><topic>Joints - drug effects</topic><topic>Joints - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Observer Variation</topic><topic>Predictive Value of Tests</topic><topic>Prospective Studies</topic><topic>Psoriasis. Parapsoriasis. Lichen</topic><topic>Reproducibility of Results</topic><topic>Severity of Illness Index</topic><topic>Skin - diagnostic imaging</topic><topic>Skin - drug effects</topic><topic>Skin - pathology</topic><topic>Spain</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Ultrasonography, Doppler</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DE AGUSTIN, J. J</creatorcontrib><creatorcontrib>MORAGUES, C</creatorcontrib><creatorcontrib>DE MIGUEL, E</creatorcontrib><creatorcontrib>MÖLLER, I</creatorcontrib><creatorcontrib>ACEBES, C</creatorcontrib><creatorcontrib>NAREDO, E</creatorcontrib><creatorcontrib>USON, J</creatorcontrib><creatorcontrib>REJON, E</creatorcontrib><creatorcontrib>MAYORDOMO, L</creatorcontrib><creatorcontrib>GARRIDO, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DE AGUSTIN, J. J</au><au>MORAGUES, C</au><au>DE MIGUEL, E</au><au>MÖLLER, I</au><au>ACEBES, C</au><au>NAREDO, E</au><au>USON, J</au><au>REJON, E</au><au>MAYORDOMO, L</au><au>GARRIDO, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A multicentre study on high-frequency ultrasound evaluation of the skin and joints in patients with psoriatic arthritis treated with infliximab</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2012-11-01</date><risdate>2012</risdate><volume>30</volume><issue>6</issue><spage>879</spage><epage>885</epage><pages>879-885</pages><issn>0392-856X</issn><eissn>1593-098X</eissn><abstract>Our objective was to describe the ultrasound features of patients with PsA in joints and skin and their changes after treatment with infliximab.
Eight hospitals recruited PsA active patients. Clinical (joint count for pain, TJC, and swelling, SJC, pain VAS, ESR, C-reactive protein and PASI) and US variables (plaque thickness, PD signal of dermal lesions, synovitis, erosions, and PD signal, assessed by 4-category ordinal scales) were independently recorded at baseline and 4, 12 and 24-week after starting treatment with infliximab. The results were analysed with paired T, Wilcoxon test, ANOVA and marginal homogeneity test.
Changes in 24 patients from baseline to last available data were significant for clinical variables, pain VAS, TJC and SJC as well as for ESR, CRP (all p<0.0005). Dermatological PASI changed from 14.6±14.9 to 2.1±4.1 and plaque thickness from 3.34±1.75 mm to 1.74±0.96 mm (both p<0.0005); synovitis and PD signal improved (both p<0.0005). Psoriatic plaque PD improved across the study (p<0.0005) with no signal increasing from 36.4% to 88.9% and positive PD signal decreasing from 63.6% to 11.1% of the plaques.
Treatment with anti-TNF-α infliximab improves the symptoms of patients with PsA at joint and psoriatic skin levels from a clinical and ultrasonographic perspective.</abstract><cop>Pisa</cop><pub>Clinical and Experimental Rheumatology</pub><pmid>23020866</pmid><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0392-856X |
| ispartof | Clinical and experimental rheumatology, 2012-11, Vol.30 (6), p.879-885 |
| issn | 0392-856X 1593-098X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1273219703 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal - therapeutic use Arthritis, Psoriatic - diagnostic imaging Arthritis, Psoriatic - drug therapy Arthritis, Psoriatic - pathology Biological and medical sciences Dermatology Diseases of the osteoarticular system Diseases of the spine Female Humans Inflammatory joint diseases Infliximab Joints - diagnostic imaging Joints - drug effects Joints - pathology Male Medical sciences Middle Aged Multivariate Analysis Observer Variation Predictive Value of Tests Prospective Studies Psoriasis. Parapsoriasis. Lichen Reproducibility of Results Severity of Illness Index Skin - diagnostic imaging Skin - drug effects Skin - pathology Spain Time Factors Treatment Outcome Ultrasonography, Doppler Young Adult |
| title | A multicentre study on high-frequency ultrasound evaluation of the skin and joints in patients with psoriatic arthritis treated with infliximab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T02%3A40%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20multicentre%20study%20on%20high-frequency%20ultrasound%20evaluation%20of%20the%20skin%20and%20joints%20in%20patients%20with%20psoriatic%20arthritis%20treated%20with%20infliximab&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=DE%20AGUSTIN,%20J.%20J&rft.date=2012-11-01&rft.volume=30&rft.issue=6&rft.spage=879&rft.epage=885&rft.pages=879-885&rft.issn=0392-856X&rft.eissn=1593-098X&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1273219703%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1273219703&rft_id=info:pmid/23020866&rfr_iscdi=true |